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Abstract 
In humans, aromatase (CYP19) gene expression is regulated via alternative promoters. Activation 
of each promoter gives rise to a CYP19 mRNA species with a unique 5'-untranslated region. 
Inhibition of aromatase has been reported to downregulate lung tumor growth. The genetic basis 
for CYP19 gene expression and aromatase activity in lung cancer remains poorly understood. We 
analyzed tissues from 15 patients with non-small cell lung cancer (NSCLC) to evaluate CYP19 
promoter usage and promoter-specific aromatase mRNA levels in NSCLC tumor tissues and 
adjacent non-malignant tissues. CYP19 promoter usage was determined by multiplex RT-PCR 
and aromatase mRNA levels were measured with real-time RT-PCR. In non-malignant tissues, 
aromatase mRNA was primarily derived from activation of CYP19 promoter I.4. Although 
promoter I.4 usage was also dominant in tumor tissues, I.4 activation was significantly lower 
compared with adjacent non-malignant tissues. Activity of promoters I.3, I.1 and I.7 was 
significantly higher in tumor tissues compared with non-malignant tissues. In 4 of 15 cases of 
non-small cell lung cancer, switching from CYP19 promoter I.4 to the alternative promoters II, 
I.1 or I.7 was observed. In 9 cases, there were significantly higher levels of aromatase mRNA in 
lung tumor tissues compared with adjacent non-malignant tissues. These findings suggest 
aberrant activation of alternative CYP19 promoters that may lead to upregulation of local 
aromatase expression in some cases of NSCLC. Further studies are needed to examine the impact 
of alternative CYP19 promoter usage on local estrogen levels and lung tumor growth.  
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Introduction 
      Aromatase catalyzes the rate-limiting step in estrogen biosynthesis, the aromatization of 
androgens. A single gene (CYP19) encodes aromatase, and activation determines the presence or 
absence of aromatase enzyme activity in cells or tissues [1]. The entire aromatase gene spans 
approximately 123 kb and is transcribed from the telomere to the centromere [1-3]. The 30-kb 3-
end of the gene contains 9 exons (II-X) that encode the aromatase protein.  The ATG translation 
initiation site is located 38 bp downstream of a common splice acceptor site in coding exon II.  
The 93-kb 5'-flanking region of the gene contains a number of tissue-specific promoters with 
unique 5'-untranslated first exons that are spliced onto a common splice junction such that each 
promoter-specific mRNA species encodes an identical aromatase protein [1].   
      The farthest upstream promoter is I.1, and its activity causes splicing of exon I.1 onto the 
common splice acceptor site, 93 kb downstream.  The most proximal promoters, the gonad-
specific promoter II and two other proximal promoters, I.3 (expressed in adipose tissue and breast 
cancer) and I.6 (expressed in bone) are located within the 1-kb region upstream of the common 
splice junction. The promoters specific for the brain (I.f) and skin (I.4) are localized at 
approximately 33 kb and 73 kb, respectively, upstream of  the common splice junction [1, 4].  In 
adipose tissue or cultured adipose fibroblasts from breast, abdomen, buttocks and thighs, 
promoters I.4 (major) and I.3/II (minor) are used [4]. 
      Estrogens contribute to differentiation and maturation in normal lung [5] and also stimulate 
growth and progression of non-small cell lung cancer (NSCLC) [6, 7]. As in breast, aromatase 
mediates the synthesis of local estrogen in lung tissues, which may affect lung tumor progression 
in estrogen receptor-expressing malignancies [8-10]. Aromatase inhibitors have recently been 
reported to repress lung tumor growth in vitro and in xenografts in nude mice [11]. 
      The molecular basis for the CYP19 gene regulation in the lung remains poorly understood. In 
the present study, we demonstrate that CYP19 promoter I.4 is dominant in both lung tumor tissue 
and non-malignant tissues, though at a lower level than in non-malignant tissues, and that there is 
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aberrant activation of alternative CYP19 promoters and increased aromatase mRNA levels in 
some NSCLC tumor tissues. 
 6 
Materials and Methods 
Patients 
      We assessed tumor tissue and adjacent non-malignant tissue from 15 patients with NSCLC. 
The patient characteristics are listed in Table 1. The subjects without a smoking history were 
regarded as non-smokers, those who had a smoking history of one year or longer but did not 
smoke as ex-smokers, and those who smoked as current smokers. The Brinkman Index was 
calculated for the ex- and current smokers based on the number of cigarettes smoked each day 
and the number of smoking years. The purpose of the study was explained, and written informed 
consent was obtained from all study patients. The study protocol was approved by the ethics 
committees of University of Fukui Hospital and Northwestern University Feinberg School of 
Medicine. Tissue samples were collected at the time of surgery or autopsy at the University of 
Fukui Hospital. All samples were stabilized at 4°C overnight by RNA-later liquid (Applied 
Biosystems, Foster City, CA) immediately after surgery or autopsy, and then moved to -20°C 
until analyses. Tumor tissue and adjacent non-malignant tissue were in the same lobe and 
approximately 10 cm apart from each other. 
 
Multiplex RT-PCR 
      To study promoter usage in the CYP19 gene by multiplex RT-PCR, we designed 9 different 
amplicons from 303 to 373 bp (Fig. 1), as described previously [12]. This method has been 
validated in 2 different reports [12, 13]. The primers used in this study were: I.1 forward, 5'-ctg 
tgc tcg gga tct tcc-3', I.2 forward, 5'-ggc ttc ctg act ttc aac ag -3', I.3 forward, 5'-cct tgt ttt gac ttg 
taa cca-3', I.4 forward, 5'-gac caa ctg gag cct gac ag-3', I.6 forward, 5'-taa att gat tgt ctt gca cag g-
3', I.7 forward, 5'-gaa gta aga ccg gag aaa ggg-3', I.8 forward, 5'- tca tat tgg gag gag ctt gg -3', PII 
forward, 5'-tcc ctt tga ttt cca cag gac tc-3', common reverse, 5'-ctc cat aca ccc ggt tgt ag-3'. The 
reverse primer was located at common exon III and labeled with 6-carboxyfluorescein [FAM] to 
quantitate promoter-specific mRNA species. The PCR reaction was set as follows: denaturation at 
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96°C for 5 min, then 45 cycles at 96°C for 30 sec, 58°C for 30 sec and 72°C for 30 sec. After 
PCR amplification, RT-PCR products were separated on an ABI3100 capillary sequencer and 
quantified by GeneScan software (Applied Biosystems). 
 
Real-time RT-PCR 
      mRNA was reverse-transcribed from total RNA using Superscript III (Invitrogen, Carlsbad, 
CA) and random hexamer primers. Real-time PCR was then performed to amplify the coding 
region of the CYP19 gene and GAPDH as a control, using TaqMan Gene Expression Assays 
(Applied Biosystems). PCR amplifications were performed in an ABI PRISM 7900 Sequence 
Detection System (Applied Biosystems) according to the manufacturer's instructions. cDNA (2 µl) 
was added to the PCR mixture in a final volume of 20 µl. Thermal conditions were 50 °C for 2 
min, 95°C for 10 min and then 40 cycles of 95°C for 15 sec and 60°C for 1 min. PCR 
amplifications were performed in triplicate. 
 
Statistical analysis 
All statistical analyses were conducted using the StatView statistical software. Statistical 
comparison of CYP19 gene promoter usage and expression levels in lung tumor and adjacent 
non-malignant tissues was done by Wilcoxon signed-ranks test or Student’s t-test. P values of 
<0.05 were considered statistically significant.
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Results 
CYP19 promoter usage in lung tumor and adjacent non-malignant tissues 
      Non-malignant lung tissues from almost all cases employed promoter I.4, though two cases 
primarily used promoters I.3/II (Fig. 2). Although I.4 was the dominant promoter used in tumor 
tissues, I.4 usage was significantly lower in lung tumor tissues compared with adjacent non-
malignant tissues. Tumor tissues also showed use of promoters I.3, I.1 and I.7 (Fig. 2). In tumor 
tissues from 4 of the 15 cases, promoter switching from I.4 to II, I.1 or I.7 was observed. These 
observations suggest aberrant activation of alternative CYP19 promoters in lung cancer.  
 
Aromatase mRNA levels in lung tumor and adjacent non-malignant tissues 
      Aromatase mRNA levels in 9 of 15 lung tumor tissues were significantly higher than those in 
adjacent non-malignant tissues (Fig. 3). A statistically significant difference in aromatase mRNA 
levels between lung tumor and corresponding non-malignant tissues was observed (Fig. 4). 
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Discussion 
       The poor long-term survival rate in patients with NSCLC has driven the search for novel 
therapeutic targets through a better understanding of the disease pathology. The findings of a 
number of previous studies suggest that treatments targeted to estrogen signaling pathways may 
have anti-tumor efficacy in lung cancer [7, 11, 14-18]. Aromatase inhibitors have been used in 
therapeutic regimens for estrogen-dependent disorders such as breast cancer, endometriosis and 
uterine fibroids, but their application in lung cancer has not been considered. Our study adds to 
the growing body of evidence that aromatase inhibition may be a new therapeutic option for 
patients with lung malignancies. 
      Our results show that non-malignant lung tissue from NSCLC patients maintained low levels 
of aromatase expression, primarily via promoter I.4, which lies 73 kb upstream of the common 
coding region. Lung tumor tissue also primarily employed promoter I.4, though at a lower level 
than adjacent non-malignant tissue. The most distal promoter, I.1, was used only minimally in 
non-malignant lung tissue, but was used at much higher levels in lung tumor tissue. Promoters I.3 
and I.7 were also upregulated in lung tumor tissue. Thus, total aromatase expression in lung 
tumor tissue was comprised of the sum of mRNA species arising from four promoters (I.4, I.1, I.3 
and I.7), while normal lung tissue aromatase expression arose almost exclusively from promoter 
I.4 activation. Future studies will determine the impact of CYP19 promoter switching in lung 
cancer on aromatase activity and local production of estrogen. 
Epithelial-stromal interactions enhance estrogen formation, desmoplastic reaction, and 
angiogenesis in a breast tumor [19, 20]. Breast cancer appears to take advantage of four 
promoters (II, I.3, I.7, and I.4) for aromatase expression [21]. The use of proximal promoters 
II/I.3 are strikingly up-regulated in adipose tissue adjacent to breast cancer and in breast cancer 
tissue per se. Aromatase is overexpressed in vascular endothelial cells of breast tumor tissue via 
promoter I.7. We observed that activity of promoters I.3, I.7 and I.4 was up-regulated in lung 
 10 
tumor tissue. Complex tumor-stromal interactions may favor angiogenesis and increased local 
estrogen concentrations in lung tumors. 
Alternative promoters of the CYP19 gene have been shown to be differentially regulated. 
Cyclic AMP (cAMP)-dependent transcription factors regulates proximal promoters PII/I.3 via 
two proximal cAMP response elements [22], whereas the glucocorticoid receptor (GR) induces 
promoter I.4 transcription via a GR binding element [23]. Interaction between the transcription 
factor GATA-2 and a specific GATA cis-regulatory element in promoter I.7 plays a critical role 
in its regulation [24]. These facts suggest that the activation of a particular CYP19 promoter may 
be specifically blocked, such that promoters found to be aberrantly activated in disease states can 
be targeted by therapeutics. In this case, a novel therapeutic strategy for estrogen-dependent 
NSCLC may involve targeting of the signaling pathways responsible for activation of promoters 
I.1, I.3 and I.7. 
      Though aromatase inhibitors are well tolerated, they can cause unwanted side effects related 
to systemic estrogen deprivation, such as bone loss. New therapeutic strategies that more 
effectively target aromatase expression and activity are needed. Our study provides new 
information on promoter usage in individual patients with NSCLC. In combination with 
information about estrogen receptor status, an understanding of CYP19 promoter usage in 
individual patients with lung cancer may lead to personalized approaches that more specifically 
suppress aromatase expression only in lung tumor tissues. 
      In the present study, we revealed that promoter I.4 was dominant in both lung tumor and non-
malignant tissues, and that the alternative promoters I.3/II, I.1 and I.7 were aberrantly and 
heterogeneously activated in the lung tumor tissues from certain patients with NSCLC. Further 
study is essential to elucidating the trans and/or cis acting factors involved in ectopic activation 
of these promoters in lung cancer, as well as the impact of CYP19 promoter switching on local 
aromatase activity and estrogen levels, and lung tumor growth and progression.
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Assessment of alternative CYP19 promoter usage. (A) Schematic of alternative tissue-specific 
exons I and promoters of the CYP19 gene. (B) RT-PCR products for multiplex PCR. 8 different 
amplicons from 303 to 373 bp were designed to detect tissue-specific first exons. 
 
Figure 2 
Tissue-specific CYP19 gene promoter usage in lung tumor and adjacent non-malignant tissues by 
multiplex RT-PCR. Significant differences in promoter usage were observed for promoters I.3, 
I.1, I.4 and I.7, indicating aberrant activation of promoters I.3, I.1, and I.7 in lung cancer. The 
horizontal line represents the median, the box encompasses the 25th to 75th percentile and error 
bars encompass the 10th to 90th percentile. *p<0.05, by Wilcoxon signed-ranks test. 
 
Figure 3 
Comparison of aromatase mRNA levels in lung tumor and adjacent non-malignant tissues. In 9 
out of 15 paired samples, there was significantly higher aromatase expression in lung tumor 
tissues compared with adjacent normal tissues. *p<0.0001, **p<0.001, ***p<0.05, †p<0.01, by 
two tailed Student’s t-test. 
 
Figure 4 
Boxplot summary of CYP19 mRNA levels in lung tumor and adjacent non-malignant tissues. 
There were significantly higher aromatase mRNA levels in lung tumor tissues compared with 
adjacent non-malignant tissues. The horizontal line represents the median, the box encompasses 
the 25th to 75th percentile and error bars encompass the 10th to 90th percentile. *p<0.05, by 
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